Request Demo
Last update 08 May 2025
Interferon gamma-1a biosimilar(Shionogi & Co., Ltd.)
Last update 08 May 2025
Overview
Basic Info
Drug Type Interferons, Biosimilar |
Synonyms IFN-γ-1a, Imunomax, Interferon gamma 1a biosimilar + [3] |
Target |
Action stimulants |
Mechanism IFNGR stimulants(Interferon gamma receptor stimulants), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (29 Sep 1989), |
RegulationOrphan Drug (Japan) |
Login to view timeline
Structure/Sequence
Sequence Code 1277669046
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Interferon gamma-1a biosimilar(Shionogi & Co., Ltd.)JPRN-jRCT2080222030
A phase 3, open-label, extension study of S-6810 in patients with mycosis fungoides or Sezary syndrome
JPRN-jRCT2080221783
A phase 2, open-label study of S-6810 in patients with mycosis fungoides or Sezary syndrome
JPRN-JapicCTI-121825
A phase 2, open-label study of S-6810 in patients with mycosis fungoides or Sezary syndrome
100 Clinical Results associated with Interferon gamma-1a biosimilar(Shionogi & Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Interferon gamma-1a biosimilar(Shionogi & Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Interferon gamma-1a biosimilar(Shionogi & Co., Ltd.)
Login to view more data
1
Literatures (Medical) associated with Interferon gamma-1a biosimilar(Shionogi & Co., Ltd.)01 Feb 1987Gan to kagaku ryoho. Cancer & chemotherapy
[Phase I study of a recombinant gamma interferon (S-6810)].
Article
Author: Takaku, F ; Ikeda, S ; Koiso, K ; Machida, T ; Maekawa, T ; Ogawa, M ; Takakura, K ; Izuo, M ; Ota, K ; Ichimaru, M
100 Deals associated with Interferon gamma-1a biosimilar(Shionogi & Co., Ltd.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Sezary Syndrome | Japan | 23 May 2014 | |
| Granulomatous Disease, Chronic | Japan | 30 Jun 1998 | |
| Kidney Neoplasms | Japan | 29 Sep 1989 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free